> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sword Health to acquire Headspace for up to $300M
- URL: https://members.americanhealthintel.com/2026-08-28-ledger/
- Published: 2026-08-28T15:59:48.000Z
- Updated: 2026-08-28T15:59:48.000Z
- Description: Plus: AusperBio raises $120M Series C for hepatitis B therapy. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: AusperBio raises $120M Series C for hepatitis B therapy. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Friday, August 28, 2026 Sword Health to acquire Headspace for up to $300M Plus: AusperBio raises $120M Series C for hepatitis B therapy. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Deal Confidence: High Sword Health, a virtual musculoskeletal care company valued above $4 billion, is paying up to $300 million in cash for Headspace, the meditation and therapy app once valued near $3 billion. The deal surfaced in a Massachusetts regulatory filing and is expected to close September 14\. It's Sword's second acquisition this year, after Kaia Health, as it builds toward a planned 2028 IPO. Why it matters A virtual care company just agreed to pay up to $300 million for a mental-health app once valued near $3 billion, a steep markdown that shows how far 2021-era digital health valuations have fallen and how the sector is consolidating around fewer, broader platforms. Sources: [STAT](https://www.statnews.com/2026/08/25/sword-health-to-acquire-headspace-per-regulatory-filing/?ref=members.americanhealthintel.com) · [Pharmaphorum](https://pharmaphorum.com/news/sword-health-buys-headspace-200m-300m-deal?ref=members.americanhealthintel.com) · [Healthcare Dive](https://www.healthcaredive.com/news/sword-health-to-acquire-headspace/828873/?ref=members.americanhealthintel.com) · [Fiercehealthcare](https://www.fiercehealthcare.com/digital-health/sword-health-acquire-headspace-all-cash-deal?ref=members.americanhealthintel.com) Deal Confidence: High AusperBio, a San Francisco biotech developing new therapies for chronic hepatitis B, a disease with no approved functional cure, closed a $120 million round to push its lead drug toward a pivotal trial. The Series C brings AusperBio's total raised since 2024 to $360 million. Proceeds advance AHB-137 into Phase 3 and fund a second candidate, AHB-171, plus combination-therapy research. Why it matters A biotech just raised $120 million to push an experimental hepatitis B drug toward a pivotal trial, a reminder of how much capital it now takes to reach late-stage testing for a disease with no approved cure. Sources: [Prnewswire](https://www.prnewswire.com/news-releases/ausperbio-completes-120-million-series-c-financing-to-advance-ahb-137-toward-potential-commercialization-and-expand-next-generation-hbv-therapies-302862321.html?ref=members.americanhealthintel.com) Also today DaVita and Humana launch value-based kidney care deal [Read](https://americanhealthintel.com/editions/2026-08-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#davita-humana-kidney-value-based-partnership) Yardstik raises $30M Series B for workforce fraud monitoring [Read](https://americanhealthintel.com/editions/2026-08-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#yardstik-workforce-fraud-series-b) 625Records$36.8BEnforcement27Deadlines163Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-28-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |